

## Liberia - Inactivated Polio Vaccine (IPV) Support

This Decision Letter sets out the Programme Terms of a Programme.

1	. (	Co	un	trv:	Li	beria

2. Grant Number: 1518-LBR-25c-X / 15-LBR-08h-Y

3. Date of Decision Letter: 01 July 2014

4. Date of the Partnership Framework Agreement: 19 August 2013

5. Programme Title: NVS, IPV routine

**6.** Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine<sup>1</sup>: Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID

8. Programme Duration<sup>2</sup>: 2015 - 2018

**9.** Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): Please note that endorsed or approved amounts for 2017 and 2018 will be communicated in due course, taking into account updated information on country requirements and following GAVI's review and approval processes.

	2015	2016	Total <sup>3</sup>
Programme Budget (US\$)	US\$352,000	US\$289,500	US\$641,500

10. Vaccine Introduction Grant: US\$125,000

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):<sup>4</sup>

Type of supplies to be purchased	2015
with GAVI funds in each year	
Number of IPV vaccines doses	294,100
Number of AD syringes	194,100
Number of safety boxes	2,150
Annual Amounts (US\$)	US\$352,000

**12.** Procurement agency: UNICEF.

13. Self-procurement: Not applicable.

<sup>3</sup> This is the total amount endorsed by GAVI for 2015 and 2016.

<sup>&</sup>lt;sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>&</sup>lt;sup>2</sup> This is the entire duration of the programme.

<sup>&</sup>lt;sup>4</sup> This is the amount that GAVI has approved.



- **14.** Co-financing obligations: GAVI's usual co-financing requirements do not apply to IPV. However, Liberia is encouraged to contribute to vaccine and/or supply costs for IPV.
- 15. Operational support for campaigns: N/A
- **16.** The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports, documents and other deliverables	Due dates
Annual Progress Report or equivalent	By May 2015

- 17. Financial Clarifications: Not applicable.
- **18. Other conditions:** If Liberia envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in its initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Liberia.

IRC Comment	Suggested way forward	Timeframe
Indicate if synergies can be	The country has responded that	Planned introduction dates: HPV
leveraged for the IPV	synergies will be drawn from	demo project October 2014,
introduction and the upcoming	introduciton of HPV and rota	Rotavirus and IPV in January
rollouts for RV and HPV demo.	also making references to the	2015.
	PIE conducted in 2011.	

Signed by,

On behalf of the GAVI Alliance

Hind Khatib-Othman

Managing Director, Country Programmes

Books (DIC)

01 July 2014